C A Poquette
Overview
Explore the profile of C A Poquette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
435
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wagner L, Neel M, Pappo A, Merchant T, Poquette C, Rao B, et al.
J Pediatr Hematol Oncol
. 2002 Mar;
23(9):568-71.
PMID: 11902298
Purpose: To determine the incidence, timing, and clinical significance of long-bone fractures in children with Ewing sarcoma family of tumors (ESFT). Patients And Methods: We retrospectively reviewed 93 consecutive cases...
2.
Venkateswaran L, Rodriguez-Galindo C, Merchant T, Poquette C, Rao B, Pappo A
Med Pediatr Oncol
. 2001 Jul;
37(1):30-5.
PMID: 11466720
Background: Fewer than 10% of Ewing family of tumors (EFT) arise in the vertebrae. Little information is available regarding the clinical presentation and outcome of these tumors. Procedure: We reviewed...
3.
Rodriguez-Galindo C, Poquette C, Daw N, Tan M, Meyer W, Cleveland J
Med Pediatr Oncol
. 2001 May;
36(6):605-11.
PMID: 11344491
Background: Preclinical studies suggest a role of insulin-like growth factor-1 (IGF-1) in the proliferation of osteosarcoma cells in vivo. The purpose of this study is to address the relationship between...
4.
Thompson J, Guichard S, Cheshire P, Richmond L, Poquette C, Ragsdale S, et al.
Cancer Chemother Pharmacol
. 2001 Apr;
47(3):211-21.
PMID: 11320664
Purpose: To develop a highly reproducible model of disseminated childhood neuroblastoma in mice to allow secondary evaluation of therapeutics against microscopic disseminated disease. Methods: CB17/Icr SCID were injected i.v. with...
5.
Athale U, Shurtleff S, Jenkins J, Poquette C, Tan M, Downing J, et al.
J Pediatr Hematol Oncol
. 2001 Feb;
23(2):99-104.
PMID: 11216714
Purpose: To compare the use of reverse transcriptase polymerase chain reaction (RT-PCR) with that of morphology-based methods for diagnosis, staging, and detection of metastatic disease in pediatric alveolar rhabdomyosarcoma (ARMS),...
6.
Spunt S, McCarville M, Kun L, Poquette C, Cain A, Brandao L, et al.
J Pediatr Hematol Oncol
. 2001 Feb;
23(2):93-8.
PMID: 11216713
Purpose: The benefit of whole-lung irradiation (WLI) for patients who have pulmonary metastases (PM) of Ewing sarcoma family tumors (ESFT) is unclear. At our institution, WLI is reserved for patients...
7.
Meyer W, Pratt C, Poquette C, Rao B, Parham D, Marina N, et al.
J Clin Oncol
. 2001 Jan;
19(1):171-82.
PMID: 11134210
Purpose: To determine the activity of carboplatin/ifosfamide in patients with previously untreated osteosarcoma and to estimate patient outcomes after a multiagent chemotherapy protocol that eliminated cisplatin. Patients And Methods: Sixty-nine...
8.
Houghton P, Stewart C, Cheshire P, Richmond L, Kirstein M, Poquette C, et al.
Clin Cancer Res
. 2000 Oct;
6(10):4110-8.
PMID: 11051264
The activity of temozolomide combined with irinotecan (CPT-11) was evaluated against eight independent xenografts (four neuroblastomas, three rhabdomyosarcomas, and one glioblastoma). In all studies, temozolomide was administered p.o. daily for...
9.
Rodriguez-Galindo C, Poquette C, Marina N, Head D, Cain A, Meyer W, et al.
J Pediatr Hematol Oncol
. 2000 Aug;
22(4):321-9.
PMID: 10959902
Purpose: Current treatment of the Ewing sarcoma family of tumors (ESFT) includes intensive multiagent chemotherapy with topoisomerase II inhibitors, alkylating agents, and granulocyte colony-stimulating factor (G-CSF). This treatment approach has...
10.
Taylor A, Shu L, Danks M, Poquette C, Shetty S, Thayer M, et al.
Med Pediatr Oncol
. 2000 Aug;
35(2):96-103.
PMID: 10918230
Background: The p53 tumor suppressor gene is the most commonly mutated gene in human cancer, and mutations arise in a wide variety of tumor types. Wild-type p53 functions as a...